Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

WesternU has one of the lowest student loan default rates nationwide


“It speaks to the dedication of our students and their undeniable quest to succeed in all pursuits,” said WesternU President Daniel R. Wilson, MD, PhD. “This would not happen without the incredible support of the Colleges, faculty, staff, alumni, and communities…to help our students succeed.”

Western University of Health Sciences has been recognized in LendEDU’s second annual report on student loan default rates for having one of the lowest default rates in the U.S. The default rate is the percentage of all outstanding student loans that a lender must write off as unpaid after a prolonged period of missed payments.

WesternU’s default rate was 0.20% in the 2017 cohort year, according to the most recent data from the Department of Education. This default rate ranked No. 35 in California and No. 138 in the entire county when ranking default rates from lowest to highest. The default rate for all California schools was 6.40% and the national student loan default rate was 9.70%. Check out the full report here: https://lendedu.com/blog/student-loan-default-rates-by-school-state-2020/

“This is really quite extraordinary,” said WesternU President Daniel R. Wilson, MD, PhD. “It speaks to the dedication of our students and their undeniable quest to succeed in all pursuits. This would not happen without the incredible support of the Colleges, faculty, staff, alumni, and communities that work together tirelessly to help our students succeed.”

“I think our graduates appreciate their education even if they had to borrow to fund it,” said WesternU Senior Vice President of Student Affairs Beverly A. Guidry, EdD. “They also take very seriously the responsibility of loan repayment. Not living up to their commitment could impact the graduate and the institution. Responsible alumni help WesternU to maintain its great reputation.”

WesternU alumni rise to the occasion in support of student scholarships, according to Senior Vice President of University Advancement Diane Abraham, PhD. WesternU received more than 40 donations totaling $93,740 as of early August. Donors have included alumni, friends, faculty, and staff, as well as the Student Government Association and even individual current students. The University has awarded funds to 65 students totaling $59,223.

“Our communities step up to offer our students hands-on experience, employment, and most importantly, scholarships to lighten the financial burden,” Abraham said. “At the onset of the pandemic, we were one of the first universities to develop a Student Emergency Support Fund.”

WesternU’s Office of Financial Aid provides support and counseling that begins during the admissions process so students understand the financial commitment they are making from the beginning.

“I think getting them right when they get in the door is good,” said Financial Aid Co-Director Theresa Poullard. “We give them a view of what is coming and the importance of staying on top of it.”

WesternU is a graduate health professions institution, so its students enter sought-after, relatively higher-paying careers. WesternU offers career paths toward 16 of the top 20 best health care jobs, according to rankings released earlier this year by U.S. News & World Report.

“It speaks to their skillset and the quality of our educational system in place, as well as to the faculty and staff of our University,” Poullard said. “Because these are graduate health professions, this is a different group of students – typically more mature, more focused. The types of programs our University offers takes strength of character. We want them to be able to achieve that goal.”

Due to the COVID-19 pandemic, Financial Aid is holding information sessions with students virtually via Microsoft Teams. Counselors encourage students to keep their loans as low as possible. Students can return borrowed funds within 120 days if they think they borrowed too much, said Financial Aid Co-Director Linda Frenza.

“We encourage students to return funds. We do that for every student who has taken out loans,” Frenza said. “We encourage our students to contact their counselors if they have specific questions, even after they graduate.”

If a graduate becomes delinquent in their loan payment, Financial Aid calls them to help them get back on track.

“We encourage students to do a one-on-one session to speak directly to their loan indebtedness,” Frenza said. “We get a lot of students making appointments to discuss specific needs during their repayment schedule.”

“To a large extent, the students themselves hold this in their hands. It’s the quality of their decision making and mature approach to managing money,” said WesternU Vice President for Finance Joshua McFarlen, CPA, CA, MPAcc. “And it’s great to have this expertise in the Financial Aid office and have that working in tandem.”

College of Podiatric Medicine Dean V. Kathleen Satterfield, DPM, FACFAOM, spoke with several CPM graduates about their student loans. She was happy to learn that they are equipped with confidence.

“They know that they are prepared with the qualities for success – excellent education, superior training and strong mentorship,” Satterfield said. “They have joined multi-specialty and orthopedic practices, independent private practices and academic health center practices. The paradigm for podiatric practice has changed drastically since I graduated in 1991 where a single podiatric physician practice was the norm. I am excited and hopeful that our graduates are leading the way to the future.”

Share article on social media or email:

Germinator Mobile Sanitizing and Disinfecting Opens First Wisconsin Franchise


Germinator has developed a patent-pending process that provides a new generation of microbial protection for both commercial and residential establishments.

We’re excited for our entrance into the Wisconsin market as we continue our rapid expansion across the U.S., said Jeff Gill, CEO of Germinator. Mike and Mitch have strong ties to the community, and we look forward to welcoming them aboard to offer the highest quality of service.

Germinator Mobile Sanitizing and Disinfecting, a broad-spectrum sanitization, disinfection and deodorization provider, is proud to announce its newest location launching as a part of its rapid national expansion. The company has opened a Germinator franchise in Kenosha, Wisconsin. Owned and operated by Mitch Costescu and Mike Roscioli, the franchise will offer door-to-door sanitizing and disinfecting services to commercial and residential properties throughout Kenosha and Racine.

“We’re excited for our entrance into the Wisconsin market as we continue our rapid expansion across the country,” said Jeff Gill, CEO of Germinator. “We aim to provide businesses and residents with a sense of assurance knowing that they have sanitized and hygienic environments during these difficult times. Mike and Mitch have strong ties to the community, and we look forward to welcoming them aboard to offer the highest quality of service.”

With a background in the food and beverage industry – Mike and Mitch understand the importance of proper sanitization and disinfection as businesses begin to reopen amid the pandemic. They were inspired to open a Germinator franchise to not only utilize at their own restaurant, but to be able to extend the service to businesses and residents throughout the area.

“The pandemic has brought upon an increased need for creating and maintaining hygienic environments,” said Mike Roscioli. “We are proud to work with Germinator to offer our services to the community. The company’s process is highly effective and uses no harsh chemicals or fumes.”

Germinator’s patent-pending methodology is the most unique and cost-effective means of providing enhanced antimicrobial protection for businesses and residences. The company first test surfaces for ATP using a luminometer to detect light that can come from cellular activity. This measurement immediately provides the level of clean on a surface.

The next step is the application of Germinator’s Genesis surface treatment. Genesis is a one-step cleaner and broad-spectrum sanitizer and disinfectant treatment that harnesses the power of hypochlorous acid (HOCl). Derived from naturally occurring minerals, Genesis not only eliminates odors at their source but kills a wide range of bacteria, including Staphylococcus aureus, MRSA, Salmonella enterica and Pseudomonas aeruginosa, and viruses including norovirus, rotavirus and adenovirus on hard, non-porous, environmental surfaces. It meets the Association of Official Agricultural Chemists (AOAC) germicidal spray standards for Hospital Grade Disinfection and is on the EPA’s N List of products determined to meet the criteria for use against SARS-CoV-2, the virus that causes COVID-19. As a result, this treatment will eliminate bacteria and viruses that may reside in your environment without the use of harsh chemicals or fumes.

Following Genesis, Germinator applies its Shield, a water-based quaternary ammonium compound that imparts a durable bacteriostatic finish. It is EPA-registered as effective against mold, mildew, algae and odor-causing bacteria. This application creates an invisible barrier that helps combat deterioration and discoloration and promotes freshness for up to three months.

The Genesis and Shield products are applied by using an electrostatic sprayer, which is the most efficient and effective means of delivering the products to the intended application sites. After Germinator’s surface treatment and protectant services, the company retests ATP levels to ensure the surfaces have achieved the intended results.

Upholding the highest standards of sanitization and disinfecting, Germinator makes claims that are scientifically supported and within EPA regulations. Germinator’s research and process are validated by the Germinator Scientific Advisory Board. The board is made up of key leaders such as Dr. Roscoe M. Moore, Jr. —who was an Assistant to the United States Surgeon General for five administrations; Dr. Harold Smith, who has extensive expertise in cell biology, molecular biology and biochemistry, along with decades of experience leading sponsored research on infectious diseases for the National Institutes of Health (NIH); Dr. David Miller, the Protocol Chair of University of Rochester Center for AIDS Research Community Advisory Board; and Chad S. Johnson, Esq., a Harvard-trained corporate, legislative, and regulatory attorney with significant experience in advising health and biotechnology companies.

“During these unprecedented times, the need to focus on sterilizing agents within our country’s airports, public spaces, and offices in order to decrease the spread of viral pathogens such as coronavirus is essential,” states Dr. Moore. “I am extremely happy to be a part of the Germinator team and lend my expertise to what I feel is an immense asset to the containment effort.”

Germinator was founded by Jeff Gill in 2015 and began national franchising in December 2019. The company continues to rapidly expand across the United States. Germinator’s mission is to provide communities with an effective method of proper sanitizing and disinfecting for businesses and households.

With Germinator, society can now have greater peace of mind and the freedom to live or work in a sanitized and disinfected environment. Businesses and residents in Kenosha and Racine can learn more by visiting https://germinatorkenosha.com/ or calling (866) 545-0243.

Share article on social media or email:

Well-Respected Gastroenterologist, Dr. David Yamini, has been Selected for Inclusion on the Super Doctors ® 2021 List for Southern California


News Image

It is such an honor to be recognized on the 2021 Southern California Super Doctors list. I truly believe that each patient should receive the personalized, compassionate and comprehensive digestive care they deserve, says Dr. David Yamini.

Dr. David Yamini has been selected by Super Doctors® as one of the top doctors in Southern California for 2021. This award is given to the area’s best doctors in various medical specialties. The list of distinguished physicians will be published in the 2021 Super Doctors magazine, which is distributed with the Los Angeles Times. Dr. Yamini, a double board-certified gastroenterologist, treats patients at his practice in Santa Monica and Beverly Hills, California. Selection for Super Doctors is a rigorous multi-step process designed to identify healthcare providers who have attained a high degree of peer recognition and professional achievement. Each year, MSP Communications undertakes a rigorous multi-phase selection process that includes a survey of doctors, independent evaluation of candidates by the research staff, a peer review of candidates by practice area and a good-standing and disciplinary check. Nationwide, Super Doctors represents an exclusive and diverse group of doctors who demonstrate outstanding skill and attention to exceptional patient care. Honorees are also found online at http://www.superdoctors.com, where selected doctors can be searched by name, medical specialty and location.

“It is such an honor to be recognized on the 2021 Southern California Super Doctors list. I truly believe that each patient should receive the personalized, compassionate and comprehensive digestive care they deserve,” says Dr. David Yamini.

More about Dr. David Yamini:

Dr. David Yamini is an accomplished physician who is double board-certified in gastroenterology and internal medicine. He brings expertise to his field, offering some of the most advanced diagnostic and therapeutic procedures for a wide variety of conditions in gastroenterology. David Yamini M.D. specializes in medical disorders of the digestive system, including inflammatory bowel disease (Crohn’s disease, ulcerative colitis), indigestion (dyspepsia), small intestinal bacterial overgrowth (SIBO) and irritable bowel syndrome (IBS). Dr. David Yamini received his medical degree from the University of Miami Miller School of Medicine. He then completed three years of internal medicine residency training at Cedars Sinai Medical Center, followed by three years of fellowship training in the Department of Gastroenterology and Liver Diseases at Loma Linda Medical Center. Dr. Yamini is an active member of the American College of Gastroenterology, American Society for Gastrointestinal Endoscopy and the American Gastroenterological Association.

Dr. David Yamini’s offices are located at 2001 Santa Monica Boulevard #1286 in Santa Monica, CA, and 9400 Brighton Way in Beverly Hills, CA. For information on the services offered by Dr. Yamini, visit http://www.davidyaminimd.com or contact his Santa Monica & Beverly Hills office directly at (310) 285-2005.

Share article on social media or email:

Mansouri Family Dental Care & Associates Opens New Lawrenceville, Georgia, Location


News Image

We are so excited for Mansouri Family Dental Care & Associates to provide the Lawrenceville community with high-quality dental care and excellence in dentistry at our new location, says Dr. Michael Mansouri.

This family-owned and operated dental practice providing exceptional care for patients of all ages. Mansouri Family Dental Care & Associates is proud to announce its expansion and the opening of a second location in Lawrenceville, GA. Mansouri Family Dental Care & Associates’ new state-of-the-art facility is located at 2401 Lawrenceville Hwy, Ste A. The brand-new clinic welcomes patients with a warm, comfortable environment and the very latest in advanced dental care technology. Husband and wife team, Dr. Azita Mansouri and Dr. Michael S. Mansouri, and Dr. Shahrokh C. Bagheri are thrilled to have the opportunity to help even more patients make informed and confident decisions about their oral health. Their newest, cutting-edge dental clinic offers a wide variety of oral health care services, ranging from general, restorative and cosmetic dentistry to orthodontics, dental implants, emergency care and pediatric dentistry. Patients will feel right at home in the newly designed office and exam rooms. The friendly, knowledgeable dental professionals are ready to provide patients with the positive and rewarding dental experience they deserve.

“We are so excited for Mansouri Family Dental Care & Associates to provide the Lawrenceville community with high-quality dental care and excellence in dentistry at our new location,” says Dr. Michael Mansouri.

More about Mansouri Family Dental Care & Associates:

Mansouri Family Dental Care & Associates is a premier family and comprehensive dental practice serving the residents of Lawrenceville, Marietta and the surrounding areas. At this well-respected dental practice, they value personalized service and make every effort to ensure that every visit is as comfortable as possible. Excellence in dentistry with personalized patient care is what you will always find at Mansouri Family Dental Care & Associates. The skilled dental team is committed to providing high-quality treatments, offering a wide menu of services from cleanings to restorative dentistry full range of cosmetic, general, implant, preventative and restorative. The friendly staff, insurance assistance and financing options will assure you a stress-free experience from your very first visit.

To learn more about the Mansouri Family Dental Care & Associates please visit https://www.naturalsmile.biz. If you would like to schedule an appointment please contact the new Lawrenceville clinic at (678) 909-1970 or call (770) 973-8222 for the Marietta location.

Share article on social media or email:

PercuSense Announces Project with the University of Melbourne funded by The Helmsley Charitable Trust to Develop a Single Sensor Continuous Glucose and Ketone Monitor


News Image

Our hope is that CGKM will be the standard of care in the future, and we are excited to support PercuSense’s work in this area.

PercuSense, an intelligent biosensor and digital health company, announced it has been awarded a $2.5 million program-related investment in the form of a loan from The Leona M. and Harry B. Helmsley Charitable Trust. PercuSense will use the funding to continue development on its novel continuous monitoring system that measures both glucose and ketones on a single minimally invasive probe. PercuSense will also support the University of Melbourne’s efforts to conduct pre-clinical testing and the first-in-human clinical studies, funded through a separate grant from Helmsley.

Diabetic ketoacidosis (DKA) is a potentially life-threatening increase in ketone levels in people with diabetes, which results in over 200,000 hospitalizations and over $5 billion in healthcare expenditure in the U.S. annually. Additionally, SGLT2 inhibitors, a promising class of glucose lowering drugs that offer additional health benefits for people with diabetes, have not yet been FDA-approved for type 1 diabetes in part because they have been shown to increase the risk of DKA in type 1 diabetes. Successful development of PercuSense’s continuous glucose and ketone monitoring system could decrease the risk of DKA and allow for more people with type 1 diabetes to reap the benefits of SGLT2 inhibitors.

With the proper information and early warning, people with diabetes can intervene early to address the underlying cause and help prevent dangerous progression and hospitalization due to DKA. Many people with diabetes are not aware when their ketone levels might be increasing, and because DKA is infrequent, they often do not have easy access to a blood ketone meter. PercuSense’s sensor system will be designed to alert users of increasing ketone levels and continue to monitor these levels after intervention. The system combines the benefits of continuous glucose monitoring while adding the safeguard of continuous ketone monitoring, which does not exist in any current commercial product.

“DKA is a constant, lurking risk for every person living with type 1 diabetes, regardless of whether they have been managing diabetes for ten days or ten years, and even more of a concern for those using or considering SGLT2 inhibitors. A system that can provide both continuous glucose and ketone monitoring (CGKM) can remove this danger, reducing the mental burden and improving the lives of people with type 1 diabetes. Our hope is that CGKM will be the standard of care in the future, and we are excited to support PercuSense’s work in this area.”

– Sean Sullivan, PhD, Type 1 Diabetes Program Officer, Helmsley Charitable Trust

The award builds off of the University of Melbourne and PercuSense’s foundational work developing and testing a continuous ketone sensor system for human feasibility studies, which was funded by a grant from Helmsley to the University of Melbourne. The sensor will employ PercuSense’s novel sensor platform technology that enables low cost, continuous measurement of multiple parameters inside the body.

PercuSense will develop the technology and complete first-in-human testing in collaboration with Dr. David O’Neal and the University of Melbourne.

“PercuSense is honored and excited to be selected by the Helmsley Charitable Trust to continue this important development program. We believe that expanding continuous monitoring beyond glucose for people with diabetes will help prevent DKA, increase peace of mind, and ultimately reduce the daily burden of managing diabetes.”

– Brian Kannard, CEO, PercuSense

About PercuSense

PercuSense is focused on developing next generation continuous sensing platforms that enable prediction, intervention, and prevention in chronic diseases and acute conditions including diabetes management and in-hospital monitoring. PercuSense’s unique technology enables low-cost monitoring of a variety of analytes, including glucose, lactate, oxygen, and ketones, to bring affordable and actionable continuous monitoring to the market. PercuSense’s vision is to provide the right information in the right moment in order to improve outcomes, cost, and burden in settings and diseases across the healthcare spectrum. For more information, please visit percusense.com.

About The Helmsley Charitable Trust

The Leona M. and Harry B. Helmsley Charitable Trust aspires to improve lives by supporting exceptional efforts in the U.S. and around the world in health and select place-based initiatives. Since beginning active grantmaking in 2008, Helmsley has committed more than $2.5 billion for a wide range of charitable purposes. The Helmsley Type 1 Diabetes Program is one of the largest private foundation funders of T1D in the nation, focused on understanding the disease, developing better treatments, and improving care and access. For more information on Helmsley and its programs, visit http://www.helmsleytrust.org.

For inquiries, please contact Brian Kannard at brian.kannard@percusense.com or (661) 425-7015.

Share article on social media or email:

Special Considerations for Complex Clinical Studies, Upcoming Webinar Hosted by Xtalks


All clinical trials face challenges, but for rare disease trials, there are additional and unique challenges. Recruiting patients with the accurate rare disease diagnosis is a significant hurdle, followed by the challenges of addressing the difficulty and strain of these diseases on the patients themselves throughout the course of the study. With many rare diseases being genetic in nature, outcomes and decisions weigh heavily on the patient families.

For rare oncology trials, it becomes even more complex, from recruiting patients with specific biomarkers and genetic characteristics to navigating complex logistics and timing with individualized therapies and addressing evolving trial designs. A high number of study sites are required to enroll a very small number of patients. Statistical significance may be limited as well, so analysis may hinge on individual patients and historical comparison. Additionally, working with regulatory authorities throughout the process is critical.

Join Deb Kientop, Vice President, Strategic Development, Oncology; Dr. Marie Bonneterre, Vice President, Medical Affairs, Oncology; and Rachael Young, Director, Feasibility, all from Synteract, in the live webinar on Tuesday, November 17, 2020 at 11am EST (4pm GMT/UK) in which they will address these challenges.

For more information or to register for this event, visit Rare Cancers: Special Considerations for Complex Clinical Studies.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

Investments aim to strengthen capabilities of DuPont™ Liveo™ healthcare silicone solutions


News Image

“We believe that DuPont Healthcare will have a positive impact on every level of the healthcare industry value chain.” says DuPont™ Liveo™ Healthcare Global Business Director Eugenio Toccalino

DuPont™ (NYSE: DD), a globally recognized leader in silicone-based technology and innovations for healthcare, is making significant investments in both capital and resources to strengthen strategic capabilities of its Liveo™ brand healthcare silicone solutions. Underscoring its long-term commitment to the healthcare industry – and confidence in its growth potential – DuPont is investing in innovation, as well as in manufacturing capabilities. These investments are focused on accelerating business growth, addressing key industry challenges arising from global megatrends, and continually improving and expanding DuPont’s ability to serve customers.

“We are working in close collaboration with our key customers to help support and drive their leadership in key healthcare industry market segments,” says DuPont™ Liveo™ Healthcare Global Business Director Eugenio Toccalino. “As a leader in Biopharma Processing, Pharma Solutions and Medical Devices, we want to enable our customers to achieve a competitive edge and grow their business in these segments. Our customers fully appreciate and reward the value of our specialists and our full commitment to the needs of the healthcare industry all the way down to the patients.”

To support customer growth and accelerate new product introductions, the targeted investments include increasing supply capacities with manufacturing improvements at DuPont’s Healthcare Industries Materials Site (HIMS) in Hemlock, Michigan, USA. Notable upgrades include extrusion capacity expansion for tubing, a new ISO 7 cleanroom, and ongoing elastomer capacity expansions with new mixing equipment for liquid silicone rubber (LSR) and high-consistency rubber (HCR).

These investments are critical for DuPont™ Liveo™ to continue addressing the key challenges and opportunities in three primary healthcare market segments, namely:

  • – Biopharma Processing, to enable cost-effective, safe manufacturing of biologics used in innovative drugs and vaccines with a wide range of Liveo™ pharma tubing and overmolded assemblies.
  • – Pharmaceutical Solutions, to enable safe, effective new therapeutic drug delivery routes with a unique offering in topical and transdermal solutions, and gastrointestinal active pharmaceutical ingredients.
  • – Medical Devices, to enable safe, convenient and effective diagnostics, monitoring


and treatment at the point of care with a broadening range of specialty medical adhesives and elastomers to support the trend for connected devices and wearables.

“Without question, these investments in the future of healthcare will help strengthen and grow the value of our DuPont™ Liveo™ brand healthcare silicone solutions,” Toccalino says. “We believe that DuPont Healthcare will have a positive impact on every level of the healthcare industry value chain.”

Dedicated to healthcare, DuPont™ Liveo™ is part of the DuPont Transportation & Industrial business unit (DuPont T&I).

###

About DuPont™ Liveo™

DuPont™ Liveo™ is a globally recognized leader in silicone-based technology for a broad range of innovations in medical devices, biopharmaceutical processing and pharmaceutical solutions. DuPont high-performance materials help create safer healthcare environments and protect the health of patients and healthcare providers worldwide. We help enable smarter healthcare and positive patient outcomes. More information can be found at liveo.dupont.com.

About DuPont Transportation & Industrial

DuPont Transportation & Industrial (T&I) delivers a broad range of technology-based products and solutions to the transportation, aerospace, electronics, healthcare, industrial and consumer markets. DuPont T&I partners with customers to drive innovation by utilizing its expertise and knowledge in polymer and materials science. DuPont T&I works with customers throughout the value chain to enable material systems solutions for demanding applications and environments. For additional information about DuPont Transportation & Industrial, visit http://www.dupont.com/transportation-industrial.html.

About DuPont

DuPont (NYSE: DD) is a global innovation leader with technology-based materials, ingredients and solutions that help transform industries and everyday life. Our employees apply diverse science and expertise to help customers advance their best ideas and deliver essential innovations in key markets including electronics, transportation, construction, water, health and wellness, food and worker safety. More information can be found at http://www.dupont.com.  

For further information contact:

Jo Klein

DuPont™ Liveo™ Healthcare

Global Business Communications Lead

Mobile: +49 173 3468246

jo.klein@dupontholding.com

Share article on social media or email:

FDAnews Announces — 15th Annual FDA Inspections vSummit, Nov. 17-18, 2020


WCG FDAnews Logo

WCG FDAnews Logo

15th Annual FDA Inspections vSummit

An FDAnews Virtual Conference

Tuesday, Nov. 17-Wednesday, Nov. 18, 2020

https://www.centerwatch.com/fdainspectionssummit

Clinical trial sponsors and sites: Come to the 15th Annual FDA Inspections Summit for insight from current and former FDA officials and industry experts about what needs to be done to be fully inspection ready.

The world of inspections is drastically different than it was before the global health pandemic. Whether this is the new normal or a temporary shift, sponsors and sites need to be ready.

During the 15th Annual FDA Inspections vSummit on Nov. 17 and 18, attendees will gain insights from industry experts on the topics that matter to you. With a track specifically dedicated to clinical trial issues, the vSummit will help one better understand unfamiliar situations brought on by the COVID-19 crisis, such as which tools will best suit a study, how to mitigate risks and ways to appropriately document consent when running a remote trial.

Spend two days with current and former FDA officials and industry experts going through everything one needs to know to navigate the complicated world of clinical trial inspections.

On the first day keynote speaker, Elizabeth Miller, Pharm.D. — Assistant Commissioner Medical Products & Tobacco Operation Office of Regulatory Affairs, FDA — will discuss the FDA’s perspectives on inspections and what to expect now and in 2021.

During the clinical track breakout, get an overview of the telemedicine innovations that can support a study’s success during the pandemic, discover ways to improve trial quality and devise an effective risk-based trial approach.

On the second day, Nov. 18, attendees will hear about the best and worst practices FDA investigators have seen during inspections and determine the steps a team can take to ensure a smooth experience. The panel — full of former FDA officials — includes:


  • David Elder, Executive Vice President Greenleaf Health, former principal


advisor to the FDA’s Associate Commissioner of Regulatory Affairs

  • David Chesney, Principal and General Manager DL Chesney Consulting, LLC,


former District Director in San Francisco, managing all FDA operations in

Northern California, Nevada and Hawaii

  • Vicky Stoakes, President, IntegRx, Inc, former CDRH Chemist, ACNA and


Investigator, Atlanta District Office Drug Cadre

  • Steve Niedelman, Lead Quality Systems and Compliance Consultant, King &


Spalding LLP, former FDA Deputy Associate Commissioner for Regulatory

Operations (moderator)

Attendees will then turn to strategies one can employ to master remote audits and procedures that will help one’s team ensure adequate informed consent in a virtual environment.

Understanding the intricacies of an inspection is critical for any clinical trial team’s success. By joining other clinical trial professionals for this focused track one will be prepared for the next inspection.

Multi-attendee discounts available!

Significant tuition discounts are available for teams of two or more from the same company.

Conference Details

15th Annual FDA Inspections vSummit

An FDAnews Virtual Conference

Tuesday, Nov. 17-Wednesday, Nov. 18, 2020

https://www.centerwatch.com/fdainspectionssummit

Tuition:

vSummit Pricing: $697

Significant team discounts are available.

Easy Ways to Register

Online: https://www.centerwatch.com/fdainspectionssummit

By phone: 888.838.5578 or 703.538.7600

About FDAnews:

FDAnews is the premier provider of domestic and international regulatory, legislative, and business news and information for executives in industries regulated by the US FDA and the European Medicines Agency. Pharmaceutical and medical device professionals rely on FDAnews’ print and electronic newsletters, books and conferences to stay in compliance with international standards and the FDA’s complex and ever-changing regulations

About CenterWatch:

Founded in 1994, CenterWatch is a trusted source and global destination for clinical trials information for both professionals and patients. CenterWatch provides proprietary data and information analysis on clinical trials through a variety of newsletters, books, databases, and information services used by pharmaceutical and biotechnology companies, CROs, SMOs, and investigative sites involved in the management and conduct of clinical trials. As a pioneer in publishing clinical trials information, CenterWatch was the first Internet site to publish detailed information about active clinical trials that could be accessed by patients and their advocates.

Share article on social media or email:

An Action Plan for the Future of Healthcare Introduced by The Beryl Institute


News Image

Reinforcing its commitment to elevate the human experience in healthcare, The Beryl Institute releases a framework for action, The New Existence. The COVID-19 crisis has shifted the foundations of healthcare forever and revealed the systemic weaknesses of healthcare globally.

Reinforcing its commitment to elevate the human experience in healthcare, The Beryl Institute releases a framework for action, The New Existence. The COVID-19 crisis has shifted the foundations of healthcare forever and revealed the systemic weaknesses of healthcare globally. As we move through his moment in history, there is not a normal to which healthcare will return, rather there is an opportunity for a new existence. The Institute, guided by a global steering team and over 1000 voices from its global community, has worked to co-create The New Existence and outline actions that will support this new future for healthcare.

Grounded in the strategic lenses that shape the experience framework and building a path to Human Experience 2030, The New Existence will align efforts and ensure the human experience at the heart of healthcare flourishes. It will ultimately lead to a future that is co-created by the diverse voices leading and engaging in healthcare globally. The New Existence is framed by four core segments and a comprehensive set of associated actions:


  • Care Teams: Redefine and advance the integrated nature of and critical role patients and their circle of support play on care teams.
  • Governance and Leadership: Reimagine, redefine and reshape the essential role of leadership in driving systematic change.
  • Models of Care & Operations: Co-design systems, processes and behaviors to deliver the best human experience.
  • Policy & Systemic Issues: Advocate for equitable institutional, governmental and payor policies, incentives and funding to drive positive change.

The Beryl Institute is offering a series of webinars and a community conversation, led by Jason A. Wolf, Ph.D., CPXP, President & CEO of The Beryl Institute, to introduce The New Existence. The dates and times for these upcoming events are listed below:

November 5, 11am ET

Webinar – Introduction to The New Existence

November 5, 9pm ET

Webinar – Introduction to The New Existence

November 6, 11am ET

Community Conversation – The New Existence

November 10, 11am ET

Webinar – Introduction to The New Existence (Portuguese Translation)

“We must acknowledge there is not a “new normal” to which we will ultimately arrive as we move through this crisis. This moment has shifted our perspective to what is and will be possible for healthcare. That future is grounded in a new existence, where much of what we have espoused and worked so hard to put in place before this crisis will remain essential,” said Wolf. “The New Existence, representing the voices of the global healthcare community, is intended to align disparate efforts, provide a framework for action and ensure the human experience at the heart of healthcare flourishes. It will ultimately steer us through this moment to a future we create together.”

To learn more about The New Existence, please visit: https://www.theberylinstitute.org/page/new-existence

###

About The Beryl Institute:

The Beryl Institute is the global community of practice committed to elevating the human experience in healthcare. We believe human experience is grounded in experiences of patients & families, those who work in healthcare and the communities they serve. We define patient experience as the sum of all interactions, shaped by an organization’s culture, that influence patient perceptions across the continuum of care.

Share article on social media or email:

Westnet Technology Assists Nation’s Firefighters


Firehouse spotlights Westnet’s First-In Fire Station Alerting System in a Quick Firehouse Chat video. Dawn Matheny, Chief Financial Officer, of Westnet, Inc. explains the impact of this system throughout the fire service. Westnet leverages new technologies to help personnel get to the scene of an emergency faster than ever before. Implementing network alerting and decreasing the time it takes to dispatch a call has proven invaluable to reducing response time. Applying an advanced text-to-speech platform allows for quick, concise verbalization of 911 call details.

As heart attacks continue to be the leading cause of death for on-duty firefighters, technology is alleviating some of the unseen stresses that firefighters live with. Imagine being awakened in the middle of the night with bright lights and a loud siren. The shock to your system is intense and takes a long time to recover from. The First-In System uses ramped, red lighting to maintain the firefighter’s night vision and a ramped, escalating soft tone is used to wake up the needed first responders. The reduction of stress from night calls is a critical part of improving the health and safety of firefighters.

About Westnet Technology

Westnet, Inc. was founded over 46 years ago in Orange County, California. Headquartered in Huntington Beach, Westnet, Inc. is currently the world’s foremost creators of emergency alerting and dispatch products used in civilian/ military fire stations and police departments throughout the country. Unique products such as the First-In Dorm Remote, First-In Alerting End Points and the First-In Satellight Controller have broken new ground in public safety notification products. Westnet products are engineered, designed, and manufactured in-house (USA) and continue to push the envelope of the First Responder industry. Westnet also has offices located in Miami Dade County, Florida and Prince William County, Virginia. Learn more about Westnet’s entire range of cutting-edge alerting products at http://www.Westnet-inc.com.

Share article on social media or email: